Pluristem Therapeutics (NASDAQ:PSTI) has been assigned a $4.00 price objective by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 158.06% from the stock’s previous close.
Other analysts have also issued reports about the company. Maxim Group set a $3.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 1st. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price objective on shares of Pluristem Therapeutics in a research note on Friday, October 6th. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Finally, ValuEngine upgraded Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $4.00.
Pluristem Therapeutics (PSTI) traded down $0.04 during trading hours on Tuesday, hitting $1.55. The company had a trading volume of 207,600 shares, compared to its average volume of 435,345. Pluristem Therapeutics has a 12 month low of $1.04 and a 12 month high of $2.12. The company has a market cap of $161.63, a price-to-earnings ratio of -4.84 and a beta of 0.09.
A number of institutional investors have recently bought and sold shares of PSTI. Psagot Investment House Ltd. grew its position in Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after buying an additional 122,347 shares in the last quarter. Heritage Investors Management Corp purchased a new position in Pluristem Therapeutics during the third quarter worth about $113,000. Finally, Jane Street Group LLC grew its position in Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after buying an additional 34,742 shares in the last quarter. Institutional investors and hedge funds own 4.31% of the company’s stock.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.